Overview
Dr. Leiman is an Associate Professor of Medicine and gastroenterologist specializing in esophageal diseases and swallowing disorders, such as eosinophilic esophagitis (EoE), motility disorders such as achalasia, and gastroesophageal reflux disease (GERD) as well as its associated complications including Barrett’s esophagus (BE). His busy clinical practice dovetails with his academic focus on health services research, including patient outcomes and clinical quality measurement. He is also a PI for several ongoing multicenter clinical trials investigating novel therapies for EoE and GERD.
Dr. Leiman has mentored numerous medical students, residents, and GI fellows on research and quality improvement projects resulting in research awards, presentations at national meetings, and peer-reviewed publications.
Current Appointments & Affiliations
Recent Publications
Marked Improvement in Food Impaction Biopsy Rate (FIBR) After Implementation of a Multicenter Behavioral Intervention.
Other Clin Gastroenterol Hepatol · April 2026 Full text Link to item CiteClinical Utility of Biomarkers for Barrett's Esophagus: Guidelines and Future Directions.
Journal Article Gastroenterol Clin North Am · March 2026 Barrett's esophagus (BE) is a major risk factor for the development of esophageal adenocarcinoma (EAC) and is the only known precursor lesion for this lethal cancer. Although BE is relatively common among patients with gastroesophageal reflux disease, most ... Full text Link to item CiteAdjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.
Journal Article Am J Gastroenterol · February 25, 2026 BACKGROUND AND AIMS: The adjunctive use of p53 immunohistochemistry (IHC) has been proposed as a potential tool to improve risk stratification in Barrett's esophagus (BE) with conflicting results. We performed a systematic review and meta-analysis to evalu ... Full text Link to item CiteRecent Grants
TARGET-GASTRO - GI-02 Pro00114153 Longitudinal, observational, non-interventional study of FDA-approved medications and other therapies used in usual clinical practice.
Clinical TrialPrincipal Investigator · Awarded by TARGET PharmaSolutions, Inc. · 2024 - 2038Dupixent Registry R668-EE-2328 EDESIA Pro00117064
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2025 - 2030A PHASE 3, MULTI-CENTER, MULTI-NATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
Clinical TrialPrincipal Investigator · Awarded by Celgene International II Sarl · 2023 - 2026View All Grants